Under the agreement, JTS will accelerate the adoption of GeneNews’ proprietary cancer tests as well as maximize the efficiency and effectiveness of GeneNews’ revenue cycle management and billing operations.
The contract agreement has an initial term of five years.
“At JTS, we are always looking to partner with innovative healthcare companies,” said Thomas Stewart, president and CEO at JTS. “GeneNews has compelling technology, which not only positively impacts patient outcomes but also reduces costs within the broader healthcare system.”
More articles on revenue cycle management:
ABPathfinder acquires Ensure Billing, becomes Pathfinder Health Innovations
Rewarding value over volume — not so easy for safety-net hospitals
Nurse practitioners vs. primary care physicians: Comparing cost of care
